Search

Amid ongoing concerns about the cost and supply of GLP-1s, a new study suggests that a wide swath of American adults would benefit from the drugs. [ABSTRACT FROM AUTHOR]

Versant has unveiled Pep2Tango, a biotech developing next-gen obesity therapeutics with multiple targets to overcome GLP-1 limitations. [ABSTRACT FROM AUTHOR]

Fierce Healthcare's Payer Summit took place in Austin, Texas on Nov. 13-14. Industry experts joined Fierce journalists to discuss issues for payers. [ABSTRACT FROM AUTHOR]

Buoyed by strong results in the most recent quarter, Hims & Hers, Doximity and Waystar all raised their 2024 revenue and profitability outlooks. [ABSTRACT FROM AUTHOR]

Metsera is riding the wave of continued enthusiasm for GLP-1 drugs and its own early-stage data to bring in a hefty $215 million series B fundraise. [ABSTRACT FROM AUTHOR]

Viking is rowing its longboat toward the front of the oral obesity therapy race, posting detailed data from its phase 1 trial. [ABSTRACT FROM AUTHOR]

Novo Nordisk has signed off on a [ABSTRACT FROM AUTHOR]

AstraZeneca may be emphasizing the potential for combinations to help its obesity pipeline stand out, but the company insists it's "playing to win." [ABSTRACT FROM AUTHOR]

Spending on GLP-1s in Medicaid has followed broader industry trends, growing significantly over the past several years, according to KFF. [ABSTRACT FROM AUTHOR]

Keep up with some of the latest headlines in the payer space with our ongoing monthly roundup for September. [ABSTRACT FROM AUTHOR]

LAS VEGAS—Demand for GLP-1s has not slowed, and employers still have not cracked the code on the perfect solution for these medications. [ABSTRACT FROM AUTHOR]

Noom is rolling out two new solutions that aim to make it easier for employers and members to manage GLP-1s, one in partnership with Waltz Health. [ABSTRACT FROM AUTHOR]

Artificial intelligence is a standout topic on the HLTH agenda this year along with GLP-1s, healthy aging, longevity and brain health. [ABSTRACT FROM AUTHOR]

Starting today, patients can access several GLP-1 medications and an over-the-counter natural weight-loss supplement exclusive to Wisp. [ABSTRACT FROM AUTHOR]

Biweekly GZR18 injections also led to a maximum weight loss of almost 12 pounds at 24 weeks, compared to just over seven pounds for semaglutide. [ABSTRACT FROM AUTHOR]

Family premiums in employer-sponsored coverage grew by 7% in 2024, averaging $25,572, according to a new report from KFF. [ABSTRACT FROM AUTHOR]

With early phase 1 data now out in the wild, metabolic disease outfit Metsera is wasting no time locking down supplies of its weight loss candidates. [ABSTRACT FROM AUTHOR]

Kailera has launched into the increasingly crowded obesity space with a portfolio of assets acquired from China and $400 million in series A funds. [ABSTRACT FROM AUTHOR]

A new analysis points to troubling trends in the U.S. healthcare market as costs continue to rise but health outcomes are declining. [ABSTRACT FROM AUTHOR]

Patients taking Ozempic were about 60% less likely to have an opioid overdose compared to those taking other diabetes drugs. [ABSTRACT FROM AUTHOR]

Dandelion Health brings together AI developers and life sciences companies to answer questions with a trove of real-world data. [ABSTRACT FROM AUTHOR]

Employers hold significant power in the healthcare industry. [ABSTRACT FROM AUTHOR]

Noom is the latest digital health company to jump into the off-label weight loss drug market to make medications more accessible to consumers. [ABSTRACT FROM AUTHOR]

Novo Nordisk has lifted the lid on a phase 1 trial of its oral amylin and GLP-1 receptor co-agonist, linking the candidate to 13.1% weight loss after 12 weeks—and highlighting the potenti [ABSTRACT FROM AUTHOR]

Biolexis Therapeutics' small molecule BLX-7006 reduced the weight of obese mice by 15% over a 28-day span. [ABSTRACT FROM AUTHOR]

Roche is holding out hopes that its injectable obesity prospect could eventually demonstrate 25% weight loss in late-stage trials, the pharma's head of metabolism R&D has told Fierce Biotech. [ABSTRACT FROM AUTHOR]

Shortly after a positive data drop for Eli Lilly's efsitora, the Indianapolis-based company is again padding the case for its weekly insulin prospect. [ABSTRACT FROM AUTHOR]

New findings for Zealand Pharma's weight loss candidate have emboldened the biotech to push the asset into a phase 2b trial. [ABSTRACT FROM AUTHOR]

Terns' decision to drop its liver disease ambitions may pay off, after the biotech posted phase 1 data from its obesity candidate. [ABSTRACT FROM AUTHOR]

These drugs work to treat diabetes and weight loss by suppressing the appetite and lowering blood sugar and A1C—which may end up being an effective treatment for Alzheimer's, heart conditions, depression, and many other conditions. [ABSTRACT FROM AUTHOR]

Higher volumes, rates and pharmaceutical expenses have so far spelled a tough 2024 for UPMC's insurance division. [ABSTRACT FROM AUTHOR]

OMNY is a national data platform. Its newest offering will help create certainty about the impacts of GLP-1s. [ABSTRACT FROM AUTHOR]

As compounded weight loss medications are typically cheaper than branded drugs, Sesame is touting the program as a more affordable alternative. [ABSTRACT FROM AUTHOR]

23andMe also reduced the size of its therapeutics team but will continue working on its two programs in clinical development. [ABSTRACT FROM AUTHOR]

Novo Nordisk has ended development of a drug candidate that it singled out as an exciting part of its pipeline earlier this year. [ABSTRACT FROM AUTHOR]

Novo Nordisk's growth has slowed in recent weeks as the company struggles to produce enough semaglutide to meet stellar demand for Wegovy and Ozempic. [ABSTRACT FROM AUTHOR]

The online health and wellness company ended the quarter with nearly 1.9 million subscribers, up 43% year-over-year. [ABSTRACT FROM AUTHOR]

"We believe that no other company in medtech is better positioned than BD to capitalize on this trend," CEO Tom Polen said on the company's second quarter earnings call. [ABSTRACT FROM AUTHOR]

The trial failed its primary endpoint, but met secondary endpoints of slower loss of brain volume and slower cognitive decline. [ABSTRACT FROM AUTHOR]

The findings add to reports popular weight loss like Wegovy and Zepbound could help curb behaviors like drinking, cannabis use and gambling. [ABSTRACT FROM AUTHOR]

Viking will launch a longship into phase 3 for the obesity drug VK2735 sooner than expected, with a clinical program expected to top $300 million. [ABSTRACT FROM AUTHOR]

A study found the risk of major cardiovascular events was reduced by 20% in patients who used the drug. [ABSTRACT FROM AUTHOR]

Innovent linked the dual agonist to improved outcomes in type 2 diabetes to tee up a filing for approval in China. [ABSTRACT FROM AUTHOR]

Telehealth weight management company Found has appointed former Spring Health executive Luca Ranaldi as its new CEO. [ABSTRACT FROM AUTHOR]

As Intuitive Surgical continues to roll out its latest da Vinci robot, the company warned that supplies may be tight for the next 12 months. [ABSTRACT FROM AUTHOR]

The pharma has put "a lot of thought into" whether Novartis could play a role in the obesity space, Vas Narasimhan explained. [ABSTRACT FROM AUTHOR]

Healthcare costs are set to rise between 7% and 8% in 2025, according to a new report from PwC. [ABSTRACT FROM AUTHOR]

Participants in a phase 1 trial lost 7.3% of their body weight after four weeks, suggesting the candidate can hold its own against rival molecules. [ABSTRACT FROM AUTHOR]

GLP-1 drugs like Ozempic, Mounjaro, Zepbound and Wegovy are being explored for treating an array of conditions including sleep apnea, kidney disease, addiction, Parkinson's and Alzheimer's. [ABSTRACT FROM AUTHOR]

Pfizer gave a leg up to two obesity biotechs with the news that an extended-release formulation oral med will be advanced. [ABSTRACT FROM AUTHOR]